Dealbreaker on MSN8d
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A DealJazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and ...
OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will ...
Blood-Brain Barrier Technology ... In conclusion, Alector’s presentation at the TD Cowen Conference underscored its commitment to advancing therapies for neurodegenerative diseases.
Hosted on MSN1mon
TD Cowen Raises Boston Scientific Corporation (BSX) Target to $115, Reaffirms ‘Buy’ Rating Ahead of Q4 ResultsA surgeon examining a patient's brain in an operating room ... On February 3rd, TD Cowen increased Boston Scientific Corporation’s (NYSE:BSX) target price to $115 from $110 and reiterated ...
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...
Brain cancers are notoriously difficult to treat ... speaking during the company’s presentation Wednesday at TD Cowen’s annual healthcare conference in Boston. “I’m a pediatric oncologist ...
KOL Event on aneurysmal Subarachnoid Hemorrhage (aSAH) ...
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback